Satellos Bioscience Inc. is a biotechnology company specializing in regenerative medicine for degenerative muscle diseases. It develops novel small-molecule therapeutics using its proprietary MyoReGenX™ platform, an automated microscopy system that analyzes muscle stem cell polarity and regeneration deficits ex vivo to identify therapeutic targets. The company's lead candidate, SAT-3247, is an oral drug in clinical development targeting Duchenne muscular dystrophy by restoring the body's innate muscle repair process disrupted by dystrophin absence, specifically through pathways like AAK1 to promote asymmetric stem cell division. Focused on unmet needs in rare diseases, Satellos Bioscience Inc. operates primarily in Canada with subsidiaries in Australia and the US, advancing a pipeline informed by stem cell biology expertise. Founded around 2018 and headquartered in Toronto, Ontario, the firm employs approximately 14-17 professionals under CEO Frank Gleeson, emphasizing innovation in muscle regeneration to address conditions where natural repair mechanisms fail.